Steris (STE) Misses Q4 EPS by 14c, Offers Guidance

Steris (NYSE: STE) reported Q4 EPS of $1.63, $0.14 worse than the analyst estimate of $1.77. Revenue for the quarter came in at $873.5 million versus the consensus estimate of $876.2 million.

GUIDANCE:

Steris sees FY2022 EPS of $7.40-$7.65, versus the consensus of $7.00.

• With Cantel Medical planned to close on June 2, STERIS is providing outlook including Cantel Medical for fiscal 2022. STERIS expects as reported revenue of approximately $4.5 billion. Constant currency organic revenue growth is expected to be in the range of 8-9% for fiscal 2022. Reflecting March 31, 2021 forward rates, currency movements are anticipated to be favorable to revenue by approximately $15 million for fiscal 2022. Adjusted earnings per diluted share are anticipated to be in the range of $7.40 - $7.65, which assumes an adjusted effective tax rate of 21-22% and a share count of approximately 99 million diluted shares.
• Free cash flow for fiscal 2022 is expected to be approximately $380 million, reflecting approximately $200 million in integration and deal related costs primarily for the purchase of Cantel Medical. Capital spending is anticipated to be approximately $320 million for the combined company.

For earnings history and earnings-related data on Steris (STE) click here.

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• UBS Downgrades JINS Holdings Inc (3046:JP) to Neutral
• Herbalife reaffirms Q3 and full-year 2026 financial guidance